Email this article KI-67 INDEX AND TYPE OF HSP70 EXPRESSION IN THE FORMATION OF PROGNOSTIC GROUPS OF PATIENTS WITH PAPILLARY THYROID CANCER
- Authors: Ivanov A.A.1, Avdalyan A.M1, Lushnikova E.L2, Molodykh O.P2, Zorkina Y.N3, Kruglova N.M1, Lazarev A.F1,4
-
Affiliations:
- Altai branch of the N.N. Blokhin National Medical Research Center of Oncology
- Institute of Molecular Pathology and Pathomorphology
- Altai Oncology Center
- Altai State Medical University
- Issue: Vol 23, No 2 (2018)
- Pages: 90-95
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/42977
- DOI: https://doi.org/10.18821/1028-9984-2018-23-2-90-95
- ID: 42977
Cite item
Full Text
Abstract
The aim of our work was to determine the possibility of stratification of papillary thyroid cancer (PTC) patients into prognosis groups depending on the Ki-67 index and the type of HSP70 expression. The study included 89 patients with a known prognosis for the period of 2005-2017, treated for PTC over the period of 2005-2013. The immunohistochemical study was carried out with Ki-67 and HSP70 antibodies on the Ventana XT Steiner device using standard protocols. The method of tissue matrices was used to standardize the study. Different variants of PTC, depending on the level of Ki-67 expression in combination with the HSP70 response allowed identifying 3 groups of PTC prognosis. The favorable prognosis group included patients with samples with cytoplasmic type of HSP70 expression and Ki-67 response < 6.3%, with mixed type of HSP70 expression and Ki-67 response < 6.3%, with cytoplasmic HSP70 expression and Ki-67 response > 6.3%. The intermediate prognosis group consisted of patients with tumors with mixed type of HSP70 expression and Ki-67 response > 6.3%, with nuclear HSP70 expression and Ki-67 response < 6.3%. The group of poor prognosis included patients with nuclear HSP70 expression and Ki-67 response > 6.3%. In the group of favorable prognosis, the 10-year survival rate was 89.6 ± 3.5%. In the intermediate prognosis group, the 10-year survival rate was 45 ± 14.5% and in the unfavorable prognosis group, no patient survives 6 years.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Anatoliy A. Ivanov
Altai branch of the N.N. Blokhin National Medical Research Center of Oncology
Email: Anatolij0199@yandex.ru
MD, researcher of the Laboratory of molecular genetic characteristics of tumors; Barnaul, 656049, Russian Federation Barnaul, 656049, Russian Federation
A. M Avdalyan
Altai branch of the N.N. Blokhin National Medical Research Center of OncologyBarnaul, 656049, Russian Federation
E. L Lushnikova
Institute of Molecular Pathology and PathomorphologyNovosibirsk, 630117, Russian Federation
O. P Molodykh
Institute of Molecular Pathology and PathomorphologyNovosibirsk, 630117, Russian Federation
Yu. N Zorkina
Altai Oncology CenterBarnaul, 656043, Russian Federation
N. M Kruglova
Altai branch of the N.N. Blokhin National Medical Research Center of OncologyBarnaul, 656049, Russian Federation
A. F Lazarev
Altai branch of the N.N. Blokhin National Medical Research Center of Oncology; Altai State Medical UniversityBarnaul, 656049, Russian Federation; Barnaul, 656038, Russian Federation
References
- Гервальд В.Я., Климачев В.В., Иванов А.А., Рагулина В.Д., Авдалян А.М., Бобров И.П., Лазарев А.Ф. Рак щитовидной железы. Международный научно-исследовательский журнал. 2014; 8-3: 17-8.
- Иванов А.А., Авдалян А.М., Гервальд В.Я., Лушникова Е.Л., Зоркина Ю.Н., Круглова Н.М., Лазарев А.Ф. Молекулярные типы в прогнозе папиллярного рака щитовидной железы на основе анализа статуса BRAF V600E и индекса экспрессии Ki-67. Российский онкологический журнал. 2017; 22(4): 188-93.
- Шкурко О.А. Клинико-морфологические и иммуногистохимические факторы прогноза при папиллярном раке щитовидной железы. Вопросы онкологии. 2008; 54(1): 19-24.
- Тимофеева Л.А., Алёшина Т.Н. Применение системы TI-RADS в дифференциальной диагностике рака щитовидной железы. Казанский медицинский журнал. 2017; 98(4): 632-6.
- Пальцев М.А., Коган Е.А., Тунцова О.И. Иммуногистохимия биомолекулярных маркёров раннего рака щитовидной железы. Архив патологии. 1997; 59(6): 18-23.
- Свиридова Т.Е., Коган Е.А., Пальцев М.А., Середин В.П. Гистологические и молекулярно-генетические маркёры злокачественности в различных вариантах папиллярного рака щитовидной железы. Архив патологии. 2002; 64(6): 19-23.
- Papotti M., Torchio B., Grassi L., Favero A., Bussolati G. Poorly differentiated oxyphilic (Hurtle cell) carcinomas of the thyroid. Am. J. Surg. Path. 1996; 20(6): 686-94.
- Ланцов Д.С. Пролиферативная активность папиллярной микрокарциномы щитовидной железы. Архив патологии. 2006; 5: 14-6.
- Ito Y., Uruno T., Takamura Y. et al. Papillary microcarcinomas of the thyroid with preoperatively detectable lymph node metastasis show significantly higher aggressive characteristics on immunohistochemical examination. Oncology. 2005; 68: 87-96. doi: 10.1159/000085701
- Sobrinho-Simoes M. Hail to the histologic grading of papillary thyroid carcinoma? Cancer. 2000; 88(8): 1766-7.
- Lorenzato M., Abboud P., Lechki C. et al. Proliferation assessment in breast cancer: a double-staining technique for AgNOR quantification in MIB-1 positive cells especially adapted for image cytometry. Micron. 2000; 31(2): 151-9.
- Van Loo G., Saelens X., van Gurp M., MacFarlane M., Martin S.J., Vandenabeele P. The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differ. 2002; 9(10): 1031-42. doi: 10.1038/sj.cdd.4401088
- Pechan P.M. Heat shock proteins and cell proliferation. FEBS Lett. 1991; 280(1): 1-4.
- Mizoguchi M., Manabe M., Kawamura Y., Kondo Y., Ishidoh K., Kominami E. et al. Deimination of 70-kD Nuclear Protein During Epidermal Apoptotic Events In Vitro. J. Histochem. Cytochem. 1998; 46(11): 1303-9.
- Wallin G., Backdahl M., Christensson B., Grimelius L., Auer G. Nuclear protein content and Ki-67 immunoreactivity in nonneoplastic and neoplastic thyroid cells. Anal. Quant. Cytol. Histol. 1992; 14(4): 296-303.
- Basolo F., Pollina L., Fontanini G., Fiore L., Pacini F., Baldanzi A. Apoptosis and proliferation in thyroid carcinoma: correlation with bcl-2 and p53 protein expression. Br. J. Cancer. 1997; 75(4): 537-41.
- Katoh R., Bray C.E., Suzuki K., Komiyama A., Hemmi A., Kawaoi A. et al. Growth activity in hyperplastic and neoplastic human thyroid determined by an immunohistochemical staining procedure using monoclonal antibody MIB-1. Hum. Pathol. 1995; 26(2): 139-46.
- Ito Y., Miyauchi A., Kakudo K., Hirokawa M., Kobayashi K., Miya A. Prognostic significance of Ki-67 labeling index in papillary thyroid carcinoma. World J. Surg. 2010; 34: 3015-21. doi: 10.1007/s00268-010-0746-3
- Sugitani I., Yanagisawa A., Shimizu A., Kato M., Fujimoto Y. Clinicopathologic and immunohistochemical studies of papillary thyroid microcarcinoma presenting with cervical lymphadenopathy. World J. Surg. 1998; 22(7): 731-7.
Supplementary files
